Opening doors for I-O
Tumor lymphangiogenesis plus immunotherapy lets the right cells in
A Science Translational Medicine study has flipped the script for tumor lymphangiogenesis by turning VEGF-C, a hallmark of poor prognosis, into a biomarker and a target for successful responses to immunotherapies.
Tumors that are surrounded by a dense network of lymphatic vessels and express high levels of lymphangiogenesis-stimulating vascular endothelial growth factor C (VEGF-C) have been associated with metastasis and poor prognosis. Study author Manuel Fankhauser